
Koichi Takahashi, M.D., Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Takahashi
Dr. Takahashi earned MD degree from Niigata University School of Medicine, Japan in 2006. He then completed two internal medicine residency, the first one in Toranomon Hospital, Tokyo, and the second in Beth Israel Medical Center, New York. He came to MD Anderson Cancer Center in 2011 as an Hematology/Oncology fellow and completed fellowship in 2014. During this time, Dr. Takahashi did postdoctoral fellowship under the mentorship of Dr. Andrew Futreal. He is board certified in Internal Medicine, Hematology and Medical Oncology. Currently, Dr. Takahashi is a Tenured Associate Professor in the Department of Leukemia with a joint appointment at the Department of Genomic Medicine. He is a physician-scientist focusing on studying pathogenesis of therapy-related myeloid neoplasms, and clonal evolution of myeloid neoplasms.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Acute Myeloid Leukemia
Myelodysplastic syndromes
Therapy-related myeloid neoplasms
Clonal hematopoiesis
Genomics
Clinical Interests
AML
Clonal hematopoiesis
Therapy-related myeloid neoplasms
MDS
Education & Training
Degree-Granting Education
2020 | Kyoto University, Kyoto, JP, Ph.D. in Medicine |
2006 | Niigata University Faculty of Medicine, Niigata, JP, MD |
Postgraduate Training
2011-2014 | Clinical Fellowship, Hematology/Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas |
2008-2011 | Clinical Residency, Internal Medicine, Beth Israel Medical Center, New York, New York |
2006-2008 | Clinical Residency, Internal Medicine, Toranomon Hospital, Tokyo |
Licenses & Certifications
2014 | American Board of Hematology |
2014 | American Board of Medical Oncology |
2014 | Texas Medical Board |
2011 | American Board of Internal Medicine |
2006 | Japanese National Medical License |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2021
Other Professional Positions
Co-founder and Chair, Beth Israel Research Society, New York, NY, 2010 - 2011
Institutional Committee Activities
Member, Moonshot Internal Advisory Board, 2022 - Present
Member, MD Anderson's Core Facility Oversight Board, 2022 - 2025
Member, Breakthroughs Advisory Council, 2022 - Present
Member, Breakthroughs Advisory Council, 2022 - Present
Member, Senate Academic Planning Committee, 2021 - Present
Member, Decisive Discoveries Focus Working Group "Key Knowledge Gaps in Biology", 2017 - 2021
Member, Data and Biospecimen Access Committee, 2017 - 2020
Honors & Awards
2022 | Leukemia & Lymphoma Scholar Award |
2022 | Team Science Award, MD Anderson Cancer Center |
2021 | Team Science Award, MD Anderson Cancer Center |
2020 | Andrew Sabin Family Fellow |
2020 | Junior Faculty Scholar Award in Basic Translational Research, American Society of hematologyu |
2016 | Khalifa Scholar Physician Scientist Award, The University of Texas MD Anderson Cancer Center |
2014 | Travel Award, European Haematology Association |
2014 | Achievement in Basic Research Award, The University of Texas MD Anderson Cancer Center |
2014 | Merit Award, American Society of Clinical Oncology |
2014 | Research Training Award for Fellows, American Society of Hematology |
2013 | Abstract Achievement Award, American Society of Hematology |
2013 | The Kimberly Patterson Leukemia Research Fellowship |
2012 | Celgene Future Leaders in Hematology Award, Celgene |
2012 | The Janice Davis Singletary Fellowship of Lymphoma Research |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2021. Clonal Evolution and Heterogeneity of Acute Myeloid Leukemia. Conference. Clonal Evolution and Heterogeneity of Acute Myeloid Leukemia. Houston, TX, US.
- 2021. Reconstructing clonal evolution in AML. Conference. Reconstructing clonal evolution in AML. Houston, TX, US.
- 2021. Next generation MRD monitoring in AML”. Conference. Next generation MRD monitoring in AML”. Houston, TX, US.
- 2019. Genomics and environmental contribution for therapy-related myeloid neoplasms. Conference. Genomics and environmental contribution for therapy-related myeloid neoplasms. Houston, TX, US.
- 2019. Clinical and intratumor heterogeneitty of leukemia. Conference. Clinical and intratumor heterogeneitty of leukemia. Houston, TX, US.
- 2019. Think Tank for Clonal Hematopoiesis. Conference. Think Tank for Clonal Hematopoiesis. Houston, TX, US.
- 2019. Think Tank for clonal hematopoiesis. Conference. Think Tank for clonal hematopoiesis. Houston, TX, US.
Regional Presentations
- 2022. Texas Single-Cell Seminar. Conference. Texas Single-Cell Seminar, US.
- 2011. Distinct Clincal Characteristic of Myeloysplastic Syndrom in Human Immunodificienty Virus Infected Patients. Conference. Distinct Clincal Characteristic of Myeloysplastic Syndrom in Human Immunodificienty Virus Infected Patients. New York, NY, US.
- 2008. Granulomatosis Arteritis presented with Eosinophilic Myositis. Conference. Granulomatosis Arteritis presented with Eosinophilic Myositis, JP.
- 2007. IgA nephropathy with a clinical course of progressive renal failure. Conference. IgA nephropathy with a clinical course of progressive renal failure, JM.
National Presentations
- 2024. Approaches to leverage single-cell sequencing in understanding AML biology and response to therapy. Invited. iWAL 2024 - International Workshop on Acute Leukemias. Pheonix, Arizona, US.
- 2022. The Genetic Mechanism of Therapy-related Myeloid Neoplasms. Conference. The Genetic Mechanism of Therapy-related Myeloid Neoplasms. Virtual Format, US.
- 2022. The role of HIPK2 in therapy-related myeloid neoplasms. Conference. The role of HIPK2 in therapy-related myeloid neoplasms. Detroit, MI, US.
- 2022. Single-cell multiomics in AML. Conference. Single-cell multiomics in AML. Boston, MA, US.
- 2022. The impact of cancer chemotherapy on genome and somatic mutations of hematopoietic stem cells. Conference. The impact of cancer chemotherapy on genome and somatic mutations of hematopoietic stem cells. Boston, MA, US.
- 2022. Clonal hematopoiesis as a hidden driver of oncologic care outcomes. Conference. AACR. New Orleans, LA, US.
- 2022. Clonal heterogeneity and evolution of AML. Conference. Clonal heterogeneity and evolution of AML. San Diego, CA, US.
- 2021. Single-cell genomics and AML. Conference. 3rd Annual iwAL Workshop. Tampa, FL, US.
- 2021. Implications of Clonal Hematopoiesis in Human Health. Conference. AACR Annual Meeting 2021. Virtual, US.
- 2020. Single Cell Insights into Myeloid Neoplasia. Conference. AMP 2020 Annual Meeting & Expo: Virtual Education & Networking Experience. Virtual, US.
- 2020. Clonal heterogeneity and evolution of acute myeloid leukemia. Conference. AACR Virtual Special Conference: Tumor Heterogeneity: From Single Cells to Clinical Impact, US.
- 2020. The Spectrum of CLonal Hematopoeiesis from CHIP to AML. Conference. SOHO 2020. Houston, TX, US.
- 2019. Single-cell DNA sequencing delineates clonal diversity of AML. Conference. Single-cell DNA sequencing delineates clonal diversity of AML. Basel.
- 2019. Delineating clonal diversity of AML by single-cell genomics. Conference. Leukemia SPORE Career Enhancement Program. St. Louis, MO, US.
- 2019. Unraveling clonal heterogeneity and evolutionary history of AML by single-cell NDA sequencing. Conference. AACR Annual Meeting. Atlanta, GA, US.
- 2017. Next Steps with CHIP and Myeloid Neoplasms-Informing Risk and Prevention. Conference. 59th American Society of Hematology Annual Meeting. Atlanta, GA, US.
International Presentations
- 2024. EVI1 in Hematopoiesis. Invited. 86th Annual Meeting of the Japanese Society of Hematology. Kyoto, JP.
- 2023. On the frontline of research for hematologic malignancies. Invited. The 82nd Annual Meeting of the Japanese Cancer Association. Yokohama, JP.
- 2022. Molecular prognostication and genomics of newly diagnosed AML. Conference. 2022 AML Clinical Roadmap. London.
- 2022. Single-cell multiomics in Cancer. Conference. Single-cell multiomics in Cancer. Yokohoma, JP.
- 2022. Clonal hematopoiesis and AML. Conference. Clonal hematopoiesis and AML. Nice, FR.
- 2022. Clonal hematopoiesis and therapy-related myeloid neoplasms. Conference. JSTCT. Yokohama, JP.
- 2022. Clonal heterogeneity and evolution in AML. Conference. Japanese Society of Medical Oncology. Kyoto, JP.
- 2021. Clonal heterogeneity and evolution in AML. Conference. Japanese Society of Hematology. Sendai, JP.
- 2021. High throughput single cell analysis in AML. Conference. Korea Society of Blood and Marrow Transplant. Virtual.
- 2021. Diagnostic and Therapeutic Implications of Myeloid Gene Panel. Conference. Novartis. Virtual, KW.
- 2020. Precision clonal mapping in acute myeloid leukemia with single-cell genomics. Conference. D5 Medical & Life Science Seminar. Virtual, US.
- 2019. Clonal heterogeneity of AML and its clinical implications. Conference. Single Cell Symposium. Helsinki, FI.
- 2019. Clonal heterogeneity in AML. Conference. 6th Annual Global Summit on Hematologic Malignancies. Whistler, CA.
- 2019. Single-cell atlas of driver mutations in AML. Conference. Single cell Biology Meets Diagnostics. Uppsala, SE.
- 2019. Leukemic Potential of clonal hematopoiesis and the association with external stressors. Conference. Clonal Hematopoiesis Workshop. Hiroshima, JP.
Formal Peers
- 2022. Grand Rounds - Virtual. Invited. Augusta, GA, US.
- 2022. TBD. Invited, Ontario, CA.
- 2022. Leukemia Academic Rounds - Virtual. Invited. Toronto, CA.
- 2022. Evolutionary trajectories of clonal hematopoiesis to myeloid malignancy. Invited. Okayama, JP.
- 2021. ENJOY Science Webinar. Invited. Houston, TX, US.
- 2021. Clonal heterogeneity in AML. Invited. Boulder, CO, US.
- 2021. Determinants of clonal hematopoiesis developments and growth. Invited. Virtual, US.
- 2021. Evolutionary History of Preleukemia and Acute Myeloid Leukemia. Invited. Houston, TX, US.
- 2020. Can Unravelling Clonal Evolution in AML Help Guide Therapy with Today's Drugs?. Invited. Dallas, TX, US.
- 2019. Single-cell atlas of acute myeloid leukemia. Invited. Uppsala, SE.
- 2019. Clinical implications of clonal hematopoiesis. Invited. Hiroshima, JP.
- 2019. Clinical implications of clonal hematopoiesis. Invited. Hiroshima, JP.
- 2018. Evolution of AML genome and epigenome during therapy. Invited. Kumamoto, JP.
- 2017. Genomic landscape of acute mixed phenotype leukemia. Invited. Fukuoka, Fukuoka, JP.
- 2017. Genomic landscape of mixed phenotype acute leukemia. Invited. Tokyo, JP.
- 2017. Molecular diagnosis of MDS. Invited. Houston, TX, US.
- 2016. Clinical residency training abroad. Invited, JP.
- 2016. Clinical implications of clonal hematopoiesis. Invited, JP.
- 2016. Molecular diagnosis of MDS. Invited. Houston, TX, US.
- 2015. Molecular diagnosis of MDS. Invited. Houston, TX, US.
- 2014. Residency training and beyond. Invited, JP.
- 2014. Residency training and clinical research in Unisted States. Invited, JP.
- 2013. Oncology Practice in United States. Invited, JP.
- 2010. Comparative analysis of residency training between Japan and United States. Invited, JP.
Grant & Contract Support
Date: | 2025 - 2026 |
Title: | Targeting HOX/MEIS pathway with Menin Inhibitor in Chronic Myelomonocytic Leukemia (CMML) |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | PI |
Date: | 2023 - 2028 |
Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
Funding Source: | NIH/NCI |
Role: | Co-PI |
ID: | FP00018561 |
Date: | 2023 - 2028 |
Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
Funding Source: | NIH/NCI |
Role: | Co-PI |
ID: | FP00018561 |
Date: | 2023 - 2026 |
Title: | Development of Targeted Therapy for Myeloid Neoplasms with Deletion 7q |
Funding Source: | Leukemia and Lymphoma Society |
Role: | PI |
ID: | FP00018512 |
Date: | 2022 - 2025 |
Title: | Targeting Clonal Hematopoiesis (CH) to Prevent Acute Myeloid Leukemia (AML) |
Funding Source: | Break Through Cancer |
Role: | PI |
ID: | PA12-0305, PA-0345 |
Date: | 2022 - 2027 |
Title: | Mutual Reinforcement between Somatic Mutations and Transcription Factors in Clonal Hematopoiesis |
Funding Source: | NIH/NCI |
Role: | Co-PI |
ID: | FP00016109 / TAMU ID: 2203832 |
Date: | 2022 - 2023 |
Title: | Impact of Chemotherapy on Hematopoietic Stem Cell Clonality and Its Association with Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms |
Funding Source: | UTMDACC MDS/AML Moon Shot – Project 4 |
Role: | PI |
Date: | 2022 - 2025 |
Title: | Molecular Pathogenesis and Therapeutic Vulnerabilities of Myelodysplastic Syndrome with del7q/-7 |
Funding Source: | Edward P. Evans Foundation |
Role: | PI |
ID: | FP00016363 |
Date: | 2022 - 2027 |
Title: | Understanding the Clonal Origin, Evolution, and Progression of Myeloid Malignancies |
Funding Source: | Leukemia & Lymphoma Society CDP Scholar Award |
Role: | PI |
ID: | FP00015572 |
Date: | 2022 - 2027 |
Title: | Biology and efficacy of Menin Inhibitors in AML therapy |
Funding Source: | NIH/NCI |
Role: | CO-I |
ID: | FP00015061/13474266 |
Date: | 2022 - 2027 |
Title: | Mutual Reinforcement between Somatic Mutations and Transcription Factors in Clonal Hematopoiesis |
Funding Source: | NIH/NCI |
Role: | CO-I |
ID: | FP00014075 |
Date: | 2022 - 2027 |
Title: | Measurable Residual Disease Detection in Acute Myeloid Leukemia by Single-cell Multi-omics |
Funding Source: | NIH/NCI |
Role: | PI |
ID: | 13380570 |
Date: | 2022 - 2025 |
Title: | The INTERCEPT Trial (Investigating Novel Theraphy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy) for Acute Myeloid Leukemia |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | CO-I |
ID: | RP220299 |
Date: | 2022 - 2025 |
Title: | Mutual Reinforcement between Somatic Mutations and Transcription Factors in Hematological Malignancies |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | CO-I |
Date: | 2022 - 2025 |
Title: | Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia by Single-cell Multi-omics |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | PI |
Date: | 2021 - 2023 |
Title: | The Role of HIPK2 in the Pathogenesis of Therapy-Related Myelodysplastic Syndrome with del7q |
Funding Source: | Dresner Foundation |
Role: | PI |
ID: | FP0001433 |
Date: | 2021 - 2024 |
Title: | Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia by Single-cell Multi-omics |
Funding Source: | Leukemia and Lymphoma Society |
Role: | PI |
ID: | FP00013624 |
Date: | 2021 - 2026 |
Title: | Preventing Leukemia and MDS by Addressing Environmental Drivers of Clonal Hematopoiesis |
Funding Source: | Leukemia and Lymphoma Society |
Role: | Collaborator |
ID: | SCOR-20649-20 |
Date: | 2021 - 2026 |
Title: | Modifiable Drivers of Expansion and Malignant Transformation from Clonal Hematopoiesis. Project 3: Contribution of Inflammation and DNA Damaging Factors to Clonal Expansion and Malignant Transformation in a Community Cohort of Older Adults |
Funding Source: | NIH/NCI |
Role: | Co-Project Leader |
ID: | FP00012779 |
Date: | 2021 - 2026 |
Title: | Modifiable Drivers of Expansion and Malignant Transformation from Clonal Hematopoiesis. Core A: Single Cell Profiling and Bioinformatics Core |
Funding Source: | NIH/NCI |
Role: | Core Leader |
ID: | 1 P01 CA265748 |
Date: | 2021 - 2025 |
Title: | Novel targeted therapies of AML stem-progenitor cells |
Funding Source: | NIH/NCI |
Role: | Co-PI |
ID: | FP00013115 |
Date: | 2021 - 2022 |
Title: | Elucidating Evolutionary History of Clonal Hematopoiesis |
Funding Source: | UTMDACC MDS/AML Moon Shot - Project 4 |
Role: | CO-I |
Date: | 2021 - 2023 |
Title: | Measurable Residual Disease (MRD) Detection Using Single Cell Multiomics in Patients with Acute Myeloid Leukemia |
Funding Source: | UTMDACC Institutional Research Grant |
Role: | Co-PI |
Date: | 2021 - 2025 |
Title: | Novel targeted therapies of AML stem-progenitor cells |
Funding Source: | NIH/NCI |
Role: | Co-PI |
ID: | FP00013115 |
Date: | 2021 - 2022 |
Title: | Elucidating the Clonal Origin and Evolutionary History of Clonal Hematopoiesis of Indeterminate Potential (CHIP) |
Funding Source: | Dressner |
Role: | PI |
ID: | FP00008822 |
Date: | 2021 - 2025 |
Title: | Novel combination therapy for AML expressing mutant RUNX1 |
Funding Source: | NIH/NCI |
Role: | Co-PI |
ID: | 1RO1CA262636 |
Date: | 2021 - 2023 |
Title: | Mapping the Genetic and Phenotypic Heterogeneity in AML and Its Clinical Significance |
Funding Source: | American Society of Hematology (ASH) |
Role: | PI |
ID: | FP00008946 |
Date: | 2021 - 2025 |
Title: | Novel combination therapy for AML expressing mutant RUNX1 |
Funding Source: | NIH/NIAMS |
Role: | Research Scientist |
ID: | 13215712 |
Date: | 2021 - 2023 |
Title: | Understanding the Genetic Predisposition and the Role of Chemo-radiation Exposures for Therapy-related Myeloma Neoplasms |
Funding Source: | V Foundation |
Role: | PI |
Date: | 2021 - 2023 |
Title: | Evolutionary Timing and Genetic Determinants of AML Transformation |
Funding Source: | Gabrielle’s Angel Foundation for Cancer Research |
Role: | PI |
ID: | FP00011843 |
Date: | 2020 - 2021 |
Title: | UTMDACC Leukemia SPORE Development Award:: Mapping the genetic and phenotypic heterogeneity in AML and its clinical significance |
Funding Source: | NIH/NCI |
Role: | PI |
ID: | P50 CA100632-18 |
Date: | 2020 - 2022 |
Title: | Clonal Diversity in Acute Myeloid Leukemia (AML) and Its Clinical Implications |
Funding Source: | The Andrew Sabin Family Foundation Fellowship |
Role: | PI |
Date: | 2020 - 2023 |
Title: | Targeting Anti-Apoptotic Pathways in MDS at that time of Progression |
Funding Source: | Evans MDS |
Role: | Collaborator |
Date: | 2020 - 2025 |
Title: | Precision Identification of Resistant and Relapse-causing Subclones in AML Treated with Decitabine and Venetoclax |
Funding Source: | NIH/NCI |
Role: | PI |
ID: | 1RO1CA255067-01 (Tracking #13009658) |
Date: | 2020 - 2021 |
Title: | Elucidating the role of immune microenvironment in the progression of clonal hematopoiesis |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | PI |
Date: | 2020 - 2023 |
Title: | Precision Characterization of Clonal Diversity in AML and its Clinical Implications |
Funding Source: | The Leukemia & Lymphoma Society |
Role: | PI |
Date: | 2020 - 2022 |
Title: | Precision Characterization of Clonal Diversity in AML and Its Clinical Implications |
Funding Source: | Emerson Collective |
Role: | PI |
Date: | 2019 - 2020 |
Title: | UTMDACC Leukemia SPORE Development Award: Optimization and advancement of molecular MRD detection in AML |
Funding Source: | NIH/NCI |
Role: | PI |
ID: | P50 CA100632-17 |
Date: | 2019 - 2024 |
Title: | PPM1D in clonal hematopoiesis and malignancies |
Funding Source: | Baylor College of Medicine |
Role: | CO-I |
ID: | R01CA237291 |
Date: | 2019 - 2019 |
Title: | Development of Single-Cell MRD Assay |
Funding Source: | Agilent Technologies |
Role: | PI |
Date: | 2018 - 2021 |
Title: | Investigating the mechanism of resistance to IDH inhibitor in AML |
Funding Source: | Conquer Cancer Foundation |
Role: | PI |
Date: | 2018 - 2019 |
Title: | Characterizing clonal heterogeneity and remodeling of AML with single cell DNA sequencing |
Funding Source: | Leukemia Research Foundation |
Role: | PI |
ID: | FP5083 |
Date: | 2018 - 2020 |
Title: | Preventing therapy-related leukemia and myelodysplastic syndromes |
Funding Source: | NIH/NCI |
Role: | CO-I |
ID: | FP00002896 |
Date: | 2018 - 2021 |
Title: | Characterizing clonal evolution and epigenomic reprogramming during IDH inhibitor therapy in acute myeloid leukemia (AML) |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | PI |
ID: | RP180489 |
Date: | 2018 - 2019 |
Title: | Characterizing clonal architecture and epigeneticremodeling of CHIP |
Funding Source: | Gilead Sciences Inc |
Role: | PI |
Date: | 2017 - 2019 |
Title: | Characterizing clonal architecture and heterogeneity of clonal hematopoiesis of indeterminate |
Funding Source: | Dresner Foundation |
Role: | PI |
Date: | 2017 - 2020 |
Title: | Identifying patients at risk of developing therapy-related myeloid neoplasms |
Funding Source: | Leukemia and Lymphoma Society |
Role: | PI |
ID: | FP00001771 |
Date: | 2017 - 2021 |
Title: | Physician Scientist Program Award |
Funding Source: | MD Anderson Cancer Center |
Role: | PI |
Date: | 2017 - 2022 |
Title: | Start Up Funds for Tenure-Track Faculty |
Funding Source: | MD Anderson Cancer Center |
Role: | PI |
Date: | 2017 - 2019 |
Title: | Understanding the mechanism of clonal evolution of CHiP to t-MDS |
Funding Source: | EvansMDS Foundation |
Role: | CO-I |
Date: | 2017 - 2018 |
Title: | Improving Prediction of Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Using Next-Generation Sequencing |
Funding Source: | Conquer Cancer Foundation |
Role: | CO-I |
ID: | FP00000098 |
Date: | 2017 - 2018 |
Title: | Targeting clonal hematopoiesis to prevent therapy related myeloid neoplasms |
Funding Source: | Leukemia Research Foundation |
Role: | PI |
ID: | FP00001936 |
Date: | 2016 - 2018 |
Title: | Early detection of therapy-related myeloid neoplasms using clonal hematopoiesis as a biomarker |
Funding Source: | Khalifa Scholar Award at The University of Texas MD Anderson Cancer Center |
Role: | PI |
Date: | 2016 - 2017 |
Title: | Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS |
Funding Source: | UTMDACC Leukemia SPORE Career Enhancement Program |
Role: | PI |
Date: | 2016 - 2017 |
Title: | NO TITLE PROVIDED |
Funding Source: | Ladies Leukemia League |
Role: | PI |
Date: | 2016 - 2017 |
Title: | Clonal hematopoiesis in cancer patients predicts development of therapy-related AML/MDS |
Funding Source: | Institutional Research Grant at The University of Texas MD Anderson Cancer Center |
Role: | PI |
Date: | 2016 - 2016 |
Title: | Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS |
Funding Source: | Mike Hogg Fund |
Role: | PI |
ID: | 1 |
Date: | 2016 - 2017 |
Title: | Identifying biomarkers that predict developments of therapy-related AML/MDS |
Funding Source: | Sabin Fellows Award |
Role: | PI |
Date: | 2015 - 2017 |
Title: | Improving the recognition, treatment, and prevention strategies for patients with inherited predispositions to hematologic malignancies |
Funding Source: | UTMDACC Leukemia SPORE Career Enhancement Award |
Role: | Co-PI |
ID: | P50 CA100632 |
Date: | 2015 - 2017 |
Title: | UTMDACC Leukemia SPORE Career Development Award: Investigating Clinical Implication of Antecedent Clonal Hematopoiesis in t-AML/t-MDS |
Funding Source: | NIH/NCI |
Role: | PI |
ID: | P50CA100632 |
Date: | 2015 - 2017 |
Title: | Clonal hematopoiesis in cancer patients predicts development of AML/MDS |
Funding Source: | Red and Charline McCombs Institute Center for Global Cancer Early Detection at The University of Texas MD Anderson Cancer Center |
Role: | PI |
ID: | 00 |
Title: | Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Translational Collaborator |
Selected Publications
Peer-Reviewed Articles
- Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
- Shi, X, Li, M, Liu, Z, Tiessen, J, Li, Y, Zhou, J, Zhu, Y, Mahesula, S, Ding, Q, Tan, L, Feng, M, Kageyama, Y, Hara, Y, Tao, JJ, Luo, X, Patras, KA, Lorenzi, PL, Huang, S, Stevens, A, Takahashi, K, Issa, GC, Samee, MH, Agathocleous, M, Nakada, D. Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40102405.
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Kumar, B, Thongon, N, Ma, F, Chien, KS, Kim, YJ, Yang, H, Loghavi, S, Tan, R, Ademà Llobet, V, Li, Z, Tanaka, T, Uryu, H, Kanagal Shamanna, R, Al-Atrash, G, Bejar, R, Banerjee, PP, Lynn Cha, S, Montalban Bravo, G, Dougherty, M, Fernandez Laurita, MC, Wheeler, N, Jia, B, Papapetrou, EP, Izzo, F, Duenas, DE, McAllen, S, Gu, Y, Todisco, G, Ficara, F, Della Porta, M, Jain, A, Takahashi, K, Dwyer, KC, Halene, S, Bertilaccio, MS, Garcia-Manero, G, Daher, M, Colla, S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40216768.
- Bayer, F, Roncador, M, Moffa, G, Morita, K, Takahashi, K, Beerenwinkel, N, Kuipers, J. Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40301336.
- Short, NJ, Kantarjian, HM, Furudate, K, Jain, N, Ravandi-Kashani, F, Karrar, OS, Loghavi, S, Nasr, L, Haddad, FG, Senapati, J, Garris, R, Takahashi, K, Jabbour, EJ. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 40369607.
- Mill, CP, Fiskus, WC, DiNardo, C, Reville, PK, Davis, JA, Birdwell, C, Das, K, Hou, H, Takahashi, K, Flores, L, Ruan, X, Su, X, Loghavi, S, Khoury, J, Bhalla, K. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38316746.
- Tseng, YJ, Kageyama, Y, Murdaugh, RL, Kitano, A, Kim, JH, Hoegenauer, KA, Tiessen, J, Smith, MH, Uryu, H, Takahashi, K, Martin, JF, Samee, MH, Nakada, D. Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38225226.
- Tseng, YJ, Kageyama, Y, Murdaugh, RL, Kitano, A, Kim, JH, Hoegenauer, KA, Tiessen, J, Smith, MH, Uryu, H, Takahashi, K, Martin, JF, Samee, MH, Nakada, D. Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38225226.
- Thongon, N, Ma, F, Baran, N, Lockyer, P, Liu, J, Jackson, C, Rose, A, Furudate, K, Wildeman, B, Marchesini, M, Marchica, V, Storti, P, Todaro, G, Ganan Gomez, I, Ademà Llobet, V, Rodriguez-Sevilla, JJ, Qing, Y, Ha, MJ, Fonseca, R, Stein, C, Class, CA, Tan, L, Attanasio, S, Garcia-Manero, G, Giuliani, N, Berrios Nolasco, DA, Santoni, A, Cerchione, C, Bueso-Ramos, CE, Konopleva, M, Lorenzi, PL, Takahashi, K, Manasanch, EE, Sammarelli, G, Kanagal Shamanna, R, Viale, A, Chesi, M, Colla, S. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38331987.
- Thongon, N, Ma, F, Baran, N, Lockyer, P, Liu, J, Jackson, C, Rose, A, Furudate, K, Wildeman, B, Marchesini, M, Marchica, V, Storti, P, Todaro, G, Ganan Gomez, I, Ademà Llobet, V, Rodriguez-Sevilla, JJ, Qing, Y, Ha, MJ, Fonseca, R, Stein, C, Class, CA, Tan, L, Attanasio, S, Garcia-Manero, G, Giuliani, N, Berrios Nolasco, DA, Santoni, A, Cerchione, C, Bueso-Ramos, CE, Konopleva, M, Lorenzi, PL, Takahashi, K, Manasanch, EE, Sammarelli, G, Kanagal Shamanna, R, Viale, A, Chesi, M, Colla, S. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38331987.
- Fiskus, WC, Mill, CP, Birdwell, C, Davis, JA, Das, K, Boettcher, S, Kadia, TM, DiNardo, C, Takahashi, K, Loghavi, S, Soth, MJ, Heffernan, TP, McGeehan, G, Ruan, X, Su, X, Vakoc, CR, Daver, N, Bhalla, K. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37055414.
- Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
- Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
- Sollier E, Kuipers J, Takahashi K, Beerenwinkel N, Jahn K. COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data. Nat Commun 14(1):4921, 2023. e-Pub 2023. PMID: 37582954.
- Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
- DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2022. PMID: 35973199.
- Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348, 2023. e-Pub 2023. PMID: 36977823.
- Ramabadran R, Wang JH, Reyes JM, Guzman AG, Gupta S, Rosas C, Brunetti L, Gundry MC, Tovy A, Long H, Gu T, Cullen SM, Tyagi S, Rux D, Kim JJ, Kornblau SM, Kyba M, Stossi F, Rau RE, Takahashi K, Westbrook TF, Goodell MA. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nat Cell Biol 25(4):528-539, 2023. e-Pub 2023. PMID: 37024683.
- Issa GC, Bidikian A, Venugopal S, Konopleva MY, DiNardo CD, Kadia TM, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SR, Takahashi K, Tang G, Loghavi S, Patel KP, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2022. PMID: 36322818.
- Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
- Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
- Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
- Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
- Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
- Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood 140(16):1753-1763, 2022. e-Pub 2022. PMID: 35512188.
- Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
- Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
- DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
- Short NJ, Kantarjian HM, Ravandi F, Konopleva MY, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang SA, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver NG, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour EJ. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
- Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
- Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun 13(1):2801, 2022. e-Pub 2022. PMID: 35589701.
- Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
- Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1253-1260, 2022. e-Pub 2022. PMID: 35132195.
- Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, Bah I, Wang W, Konoplev S, Medeiros LJ, Pemmaraju N, Khoury JD, Wang SA. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343-1350, 2022. e-Pub 2022. PMID: 35279700.
- Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1448, 2022. e-Pub 2022. PMID: 35411096.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
- El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 57(3):370-376, 2022. e-Pub 2022. PMID: 34992253.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
- Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
- Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
- Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2022. PMID: 34135465.
- Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):298, 2022. e-Pub 2022. PMID: 34876697.
- Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience. Blood Adv 5(23):5415-5419, 2021. e-Pub 2021. PMID: 34525185.
- Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
- Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
- Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
- Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 127(18):3381-3389, 2021. e-Pub 2021. PMID: 34138471.
- Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
- DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
- Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
- Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
- Shi X, Jiang Y, Kitano A, Hu T, Murdaugh RL, Li Y, Hoegenauer KA, Chen R, Takahashi K, Nakada D. Nuclear NAD+ homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. Sci Adv 7(30), 2021. e-Pub 2021. PMID: 34290089.
- Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
- Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
- Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun 12(1):2607, 2021. e-Pub 2021. PMID: 33972549.
- Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2021. e-Pub 2021. PMID: 33972555.
- Stuani L, Sabatier M, Saland E, Cognet G, Poupin N, Bosc C, Castelli FA, Gales L, Turtoi E, Montersino C, Farge T, Boet E, Broin N, Larrue C, Baran N, Cissé MY, Conti M, Loric S, Kaoma T, Hucteau A, Zavoriti A, Sahal A, Mouchel PL, Gotanègre M, Cassan C, Fernando L, Wang F, Hosseini M, Chu-Van E, Le Cam L, Carroll M, Selak MA, Vey N, Castellano R, Fenaille F, Turtoi A, Cazals G, Bories P, Gibon Y, Nicolay B, Ronseaux S, Marszalek JR, Takahashi K, DiNardo CD, Konopleva M, Pancaldi V, Collette Y, Bellvert F, Jourdan F, Linares LK, Récher C, Portais JC, Sarry JE. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med 218(5), 2021. e-Pub 2021. PMID: 33760042.
- Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
- Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine. Am J Hematol 96(5):589-598, 2021. e-Pub 2021. PMID: 33639000.
- Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
- Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
- Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
- Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
- Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
- Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
- Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
- Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
- Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
- Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
- Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5996, 2020. e-Pub 2020. PMID: 33214561.
- Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
- Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
- Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52(11):1219-1226, 2020. e-Pub 2020. PMID: 33106634.
- Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5327, 2020. e-Pub 2020. PMID: 33087716.
- Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
- DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
- Wang W, Beird H, Kroll CJ, Hu S, Bueso-Ramos CE, Fang H, Tang G, Tang Z, Wang F, Takahashi K, You MJ, Khoury JD, Medeiros LJ, Futreal PA. T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. Leukemia 34(9):2509-2512, 2020. e-Pub 2020. PMID: 32099038.
- Aitken MJL, Benton CB, Wang F, Zhang J, Herbrich SM, Takahashi K, Bueso-Ramos CE, Short NJ. 33 years later: Two distinct cases of acute lymphoblastic leukemia in one patient. Am J Hematol 95(9):1117-1120, 2020. e-Pub 2020. PMID: 32356323.
- Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
- Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
- Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
- Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
- Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
- Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126(4):765-774, 2020. e-Pub 2020. PMID: 31742675.
- Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
- Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
- Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2020. PMID: 31553487.
- Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
- Hu T, Morita K, Hill MC, Jiang Y, Kitano A, Saito Y, Wang F, Mao X, Hoegenauer KA, Morishita K, Martin JF, Futreal PA, Takahashi K, Nakada D. PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells. Blood 134(7):614-625, 2019. e-Pub 2019. PMID: 31270104.
- Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134(1):59-73, 2019. e-Pub 2019. PMID: 31023702.
- Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer 125(13):2233-2241, 2019. e-Pub 2019. PMID: 30861111.
- Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
- Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. e-Pub 2019. PMID: 31076409.
- Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. e-Pub 2019. PMID: 30902805.
- Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv 3(4):508-518, 2019. e-Pub 2019. PMID: 30760466.
- Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
- Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
- Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, Vassiliou G, Futreal PA, Donehower LA, Takahashi K, Goodell MA. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell 23(5):700-713.e6, 2018. e-Pub 2018. PMID: 30388424.
- Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
- Pellegrino M, Sciambi A, Treusch S, Durruthy-Durruthy R, Gokhale K, Jacob J, Chen TX, Geis JA, Oldham W, Matthews J, Kantarjian H, Futreal PA, Patel K, Jones KW, Takahashi K, Eastburn DJ. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res 28(9):1345-1352, 2018. e-Pub 2018. PMID: 30087104.
- Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
- Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
- Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol 36(18):JCO2017776757, 2018. e-Pub 2018. PMID: 29702001.
- Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
- Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2018. PMID: 29266206.
- Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol 4(2):230-234, 2018. e-Pub 2018. PMID: 28859185.
- Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Influence of IDH on FLT3-ITD status in newly diagnosed AML. Leukemia 31(11):2526-2529, 2017. e-Pub 2017. PMID: 28751773.
- Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
- Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123(16):3050-3060, 2017. e-Pub 2017. PMID: 28387922.
- Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol 92(7):599-606, 2017. e-Pub 2017. PMID: 28370097.
- Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
- Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100-111, 2017. e-Pub 2017. PMID: 27923552.
- Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer 122(22):3484-3491, 2016. e-Pub 2016. PMID: 27463065.
- Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
- Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
- Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
- DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 30(4):980-4, 2016. e-Pub 2016. PMID: 26228814.
- Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2016. PMID: 26479889.
- Vitale C, Lu X, Abderrahman B, Takahashi K, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol 90(11):E211-2, 2015. e-Pub 2015. PMID: 26257212.
- Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
- DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732-6, 2015. e-Pub 2015. PMID: 26016821.
- Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol 90(7):E134-5, 2015. e-Pub 2015. PMID: 25801490.
- Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 122(23):3784-6, 2013. e-Pub 2013. PMID: 24068492.
- Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11; quiz 2920, 2013. e-Pub 2013. PMID: 23896412.
- Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
- Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
- Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, Ghosh A, Hanash AM, Tran HT, Moore MA, van den Brink MR. Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 15(3):309-16, 2013. e-Pub 2013. PMID: 23434824.
- Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M, Yamamoto H, Asano-Mori Y, Matsuno N, Masuoka K, Wake A, Miyakoshi S, Ohashi K, Taniguchi S. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood 116(4):649-52, 2010. e-Pub 2010. PMID: 20439618.
Review Articles
- Takahashi K, Tanaka T. Clonal evolution and hierarchy in myeloid malignancies. Trends Cancer 9(9):707-715, 2023. e-Pub 2023. PMID: 37302922.
- DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. e-Pub 2018. PMID: 29682723.
- Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 14(10):703-18, 2013. e-Pub 2013. PMID: 24022702.
Professional Educational Materials
- Takahashi K. Management of clonal hematopoiesis in cancer patients, 2021.
Other Articles
- Fiskus, WC, Mill, CP, Birdwell, C, Davis, JA, Das, K, Boettcher, S, Kadia, TM, DiNardo, C, Takahashi, K, Loghavi, S, Soth, MJ, Heffernan, TP, McGeehan, G, Ruan, X, Su, X, Vakoc, CR, Daver, N, Bhalla, K Correction to. Blood cancer journal 15(1), 2025. PMID: 40399254.
Editorials
- Takahashi K. Untangling the Relationship between Clonal Hematopoiesis and Ovarian Cancer Therapies. J Natl Cancer Inst 114(4):487-488, 2022. PMID: 34963009.
- Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol 37(1):7-11, 2019. PMID: 30403571.
- Takahashi K. AML: Predicting the Unpredictable. Cell Stem Cell 23(2):162-163, 2018. PMID: 30075128.
- Takahashi K. Ups and downs of CHIP. Blood 131(16):1773-1774, 2018. PMID: 29674353.
Letters to the Editor
- Zhou, T, Curry, CV, Khanlari, M, Shi, M, Cui, W, Peker, D, Chen, W, Wang, E, Gao, J, Shen, Q, Xie, W, Jelloul, FZ, King, RL, Yuan, J, Wang, X, Zhao, C, Obiorah, IE, Courville, E, Nomura, E, Cherian, S, Xu, ML, Burack, WR, Liu, Hx, Jabbour, EJ, Takahashi, K, Wang, W, Wang, SA, Khoury, J, Medeiros, LJ, Hu, S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood cancer journal 14, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
- Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129: 2584-2587, 2017.
- Montalban-Bravo, Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. N Engl J Med 376: 796-7, 2017.
Patient Reviews
CV information above last modified September 03, 2025